Effect on Adrenal Function of Budesonide Versus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
National Institute for Clinical Excellence (NICE) guidelines recommend high dose inhaled
steroids for patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD, a
common chronic disease related to smoking) who are having two or more exacerbations requiring
treatment with antibiotics or oral steroids in a 12 month period. The preparations licensed
for this indication commercially available are Symbicort® and Seretide®. High dose inhaled
steroids (contained in both) can cause suppression of the adrenal glands. The investigators
want to assess adrenal suppression caused by the two preparations and compare. The results
could guide investigators in prescribing these preparations.
Phase:
Phase 4
Details
Lead Sponsor:
Hull and East Yorkshire Hospitals NHS Trust Hull University Teaching Hospitals NHS Trust
Treatments:
Budesonide Budesonide, Formoterol Fumarate Drug Combination Fluticasone Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Fluticasone-Salmeterol Drug Combination Formoterol Fumarate Salmeterol Xinafoate